Jiangsu Sihuan Biopharmaceutical

Jiangsu Sihuan Bioengineering Co., Ltd. is a publicly traded Chinese biopharmaceutical company specializing in the development and commercialization of recombinant protein therapeutics. Founded in the early 1990s, it was one of the first enterprises in China to industrialize genetic engineering technologies for medicine. The company's product portfolio is centered on cytokines, including Interleukin-2, Interferon α-2b, and Granulocyte Colony-Stimulating Factor, which are used to treat various cancers and viral infections. Its operations are primarily conducted through its subsidiary, Beijing Sihuan Biopharmaceutical Co., Ltd., which maintains large-scale GMP manufacturing facilities. Jiangsu Sihuan continues to focus on the oncology and hematology markets within mainland China.